Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bo R Rueda

Showing results (21-30 of 127) with videos related to

Pageof 13
Sort By:
American Journal of Obstetrics and Gynecology|December 3, 2013
Longitudinal expression of Toll-like receptors on dendritic cells in uncomplicated pregnancy and postpartumBrett C Young, Aleksandar K Stanic, Britta Panda, et al.
Journal of Assisted Reproduction and Genetics|October 17, 2014
The impact of vitrification on murine germinal vesicle oocyte In vitro maturation and aurora kinase A protein expressionJoseph O Doyle, Ho Joon Lee, Kaisa Selesniemi, et al.
Frontiers in Bioscience (Landmark Edition)|January 4, 2011
Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancerMichael D Curley, Leslie A Garrett, John O Schorge, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2004
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting SubstanceElizabeth J Renaud, David T MacLaughlin, Esther Oliva, et al.
Cancer Drug Resistance (Alhambra, Calif.)|July 17, 2023
The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancerSara Bouberhan, Liron Bar-Peled, Yusuke Matoba, et al.
Journal of Ovarian Research|November 5, 2014
Notch signaling in serous ovarian cancerJolijn W Groeneweg, Rosemary Foster, Whitfield B Growdon, et al.
Cancers|November 2, 2019
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem CellsChiara Bellio, Celeste DiGloria, David R Spriggs, et al.
Cancers|June 4, 2020
Galectins and Ovarian CancerChisa Shimada, Rui Xu, Linah Al-Alem, et al.
Gynecologic Oncology|March 29, 2016
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutationSilvia F Hernandez, Sarah Chisholm, Darrell Borger, et al.
Plos One|August 23, 2012
Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestinAlok Pant, Irene I Lee, Zhenxiao Lu, et al.
Pageof 13

Showing results (21-30 of 127) with videos related to

Sort By:
Pageof 13
American Journal of Obstetrics and Gynecology|December 3, 2013
Longitudinal expression of Toll-like receptors on dendritic cells in uncomplicated pregnancy and postpartumBrett C Young, Aleksandar K Stanic, Britta Panda, et al.
Journal of Assisted Reproduction and Genetics|October 17, 2014
The impact of vitrification on murine germinal vesicle oocyte In vitro maturation and aurora kinase A protein expressionJoseph O Doyle, Ho Joon Lee, Kaisa Selesniemi, et al.
Frontiers in Bioscience (Landmark Edition)|January 4, 2011
Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancerMichael D Curley, Leslie A Garrett, John O Schorge, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2004
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting SubstanceElizabeth J Renaud, David T MacLaughlin, Esther Oliva, et al.
Cancer Drug Resistance (Alhambra, Calif.)|July 17, 2023
The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancerSara Bouberhan, Liron Bar-Peled, Yusuke Matoba, et al.
Journal of Ovarian Research|November 5, 2014
Notch signaling in serous ovarian cancerJolijn W Groeneweg, Rosemary Foster, Whitfield B Growdon, et al.
Cancers|November 2, 2019
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem CellsChiara Bellio, Celeste DiGloria, David R Spriggs, et al.
Cancers|June 4, 2020
Galectins and Ovarian CancerChisa Shimada, Rui Xu, Linah Al-Alem, et al.
Gynecologic Oncology|March 29, 2016
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutationSilvia F Hernandez, Sarah Chisholm, Darrell Borger, et al.
Plos One|August 23, 2012
Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestinAlok Pant, Irene I Lee, Zhenxiao Lu, et al.
Pageof 13